COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Telmisartan Versus Ramipril After Acute Coronary Syndrome (TERACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00702936
Recruitment Status : Unknown
Verified June 2008 by Catholic University of the Sacred Heart.
Recruitment status was:  Recruiting
First Posted : June 20, 2008
Last Update Posted : June 20, 2008
Information provided by:
Catholic University of the Sacred Heart

Brief Summary:
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Myocardial Infarction Coronary Disease Drug: TELMISARTAN Drug: RAMIPRIL Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome
Study Start Date : November 2007
Estimated Primary Completion Date : August 2008
Estimated Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: R
Twenty-five patients assigned to ramipril 5 mg daily
5 mg daily

Active Comparator: T
Twenty-five patients assigned to Telmisartan 80 mg daily
80 mg daily

Primary Outcome Measures :
  1. High sensitivity C-Reactive Protein [ Time Frame: 20 days after hospital discharge ]

Secondary Outcome Measures :
  1. Endothelial Progenitor Cells [ Time Frame: 20 days after hospital discharge ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
  • presence of ECG ischemic changes,
  • angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
  • successful coronary revascularization of at least one culprit coronary vessel.

Exclusion Criteria:

  • Age>80 years, current ACE inhibitor or ARB treatment,
  • ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
  • ECG abnormalities that could affect the recognition of ST segment shift,
  • recent or chronic infective or inflammatory diseases,
  • malignancy, and myocardial infarction,
  • surgery or trauma in the previous month.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00702936

Layout table for location contacts
Contact: Italo Porto, MD, PhD 0039(0)6-30154127
Contact: Italo Porto, MD, PhD

Layout table for location information
Catholic University of the Sacred Heart Recruiting
Rome, Italy, 00168
Contact: Italo Porto, MD, PhD   
Contact: Luca Di Vito, MD   
Principal Investigator: Italo Porto, MD, PhD         
Sub-Investigator: Luca Di Vito, MD         
Sponsors and Collaborators
Catholic University of the Sacred Heart
Layout table for investigator information
Principal Investigator: Italo Porto, MD, PhD Catholic University of the Sacred Heart
Principal Investigator: Luca Di Vito, MD Catholic University of the Sacred Heart
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Catholic University of the Sacred Heart Identifier: NCT00702936    
Other Study ID Numbers: ILG-1
First Posted: June 20, 2008    Key Record Dates
Last Update Posted: June 20, 2008
Last Verified: June 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Acute Coronary Syndrome
Coronary Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors